AB2 Bio Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $20.6M

  • Investors
  • 2

AB2 Bio General Information

Description

Developer of therapies designed for the treatment of inflammatory diseases. The company develops treatments and medicines for inflammatory and autoimmune diseases with unmet medical needs, enabling medical practitioners to not only treat the symptoms but also target the underlying causes of inflammation-based diseases.

Contact Information

Website
www.ab2bio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • EPFL Innovation Park
  • Building B, 4th Floor
  • 1015 Lausanne
  • Switzerland
+41 021
Primary Industry
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • EPFL Innovation Park
  • Building B, 4th Floor
  • 1015 Lausanne
  • Switzerland
+41 021

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AB2 Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 01-Feb-2023 $20.6M Completed Clinical Trials - Phase 3
2. Later Stage VC (Series B) 14-Jan-2016 Completed Startup
1. Accelerator/Incubator Completed Startup
To view AB2 Bio’s complete valuation and funding history, request access »

AB2 Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapies designed for the treatment of inflammatory diseases. The company develops treatments and medicine
Drug Discovery
Lausanne, Switzerland

Gaithersburg, MD
 

Hennigsdorf, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AB2 Bio Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD
Adrenomed Venture Capital-Backed Hennigsdorf, Germany
Celsius (Biotechnology) Formerly VC-backed Cambridge, MA
Bellicum Pharmaceuticals Formerly VC-backed Houston, TX
Evox Therapeutics Venture Capital-Backed Oxford, United Kingdom
You’re viewing 5 of 8 competitors. Get the full list »

AB2 Bio Patents

  • 33

    Total Documents Applications and Grants

  • Total Patents Families

  • 18

    Granted

  • 15

    Pending

  • Expiring in next 12 mo

AB2 Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3185868-A1 Avoiding or minimizing side-effects related to car-t-cell therapy Pending 24-Jul-2020
AU-2021312347-A1 Avoiding or minimizing side-effects related to car-t-cell therapy Pending 24-Jul-2020
EP-3943097-A1 Car-t cell therapy Pending 24-Jul-2020
US-20220401476-A1 Car-t-cell therapy Pending 24-Jul-2020
EP-4185313-A1 Avoiding or minimizing side-effects related to car-t-cell therapy Pending 24-Jul-2020 C07K16/244
To view AB2 Bio’s complete patent history, request access »

AB2 Bio Executive Team (7)

Name Title Board Seat
Djordje Filipovic Ph.D Chief Executive Officer
Fernando Cunha Chief Financial Officer
Barthélemy Helg Co-Founder & Board Member
Erich Hunziker Ph.D Chairman
You’re viewing 4 of 7 executive team members. Get the full list »

AB2 Bio Board Members (8)

Name Representing Role Since
Adriano Aguzzi MD Self Board Member
Andrea Pfeifer Ph.D Self Chairwoman
Barthélemy Helg AB2 Bio Co-Founder & Board Member
Bénédict Hentsch Self Board Member
Diego Braguglia Ph.D VI Partners Board Member
You’re viewing 5 of 8 board members. Get the full list »

AB2 Bio Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
VI Partners Venture Capital Minority
EPFL Innovation Park Accelerator/Incubator
To view AB2 Bio’s complete investors history, request access »

Ready to get started?

Request a free trial

AB2 Bio FAQs

  • When was AB2 Bio founded?

    AB2 Bio was founded in 2010.

  • Who is the founder of AB2 Bio?

    Avinoam Kadouri and Barthélemy Helg are the founders of AB2 Bio.

  • Who is the CEO of AB2 Bio?

    Djordje Filipovic Ph.D is the CEO of AB2 Bio.

  • Where is AB2 Bio headquartered?

    AB2 Bio is headquartered in Lausanne, Switzerland.

  • What industry is AB2 Bio in?

    AB2 Bio’s primary industry is Drug Discovery.

  • Is AB2 Bio a private or public company?

    AB2 Bio is a Private company.

  • What is AB2 Bio’s current revenue?

    The current revenue for AB2 Bio is .

  • How much funding has AB2 Bio raised over time?

    AB2 Bio has raised $41.7M.

  • Who are AB2 Bio’s investors?

    VI Partners and EPFL Innovation Park have invested in AB2 Bio.

  • Who are AB2 Bio’s competitors?

    NexImmune, Adrenomed, Celsius (Biotechnology), Bellicum Pharmaceuticals, and Evox Therapeutics are some of the 8 competitors of AB2 Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »